ASPHF
Price
$5.83
Change
+$0.40 (+7.38%)
Updated
Jan 22 closing price
Capitalization
3.44B
NURPF
Price
$8.81
Change
-$0.05 (-0.56%)
Updated
Jun 16 closing price
Capitalization
1.17B
Interact to see
Advertisement

ASPHF vs NURPF

Header iconASPHF vs NURPF Comparison
Open Charts ASPHF vs NURPFBanner chart's image
ASCENTAGE PHARMA GROUP
Price$5.83
Change+$0.40 (+7.38%)
Volume$400
Capitalization3.44B
Neuren Pharmaceuticals
Price$8.81
Change-$0.05 (-0.56%)
Volume$375
Capitalization1.17B
ASPHF vs NURPF Comparison Chart in %
Loading...
NURPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASPHF vs. NURPF commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASPHF is a Hold and NURPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ASPHF: $5.82 vs. NURPF: $8.81)
Brand notoriety: ASPHF and NURPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASPHF: 100% vs. NURPF: 28%
Market capitalization -- ASPHF: $3.44B vs. NURPF: $1.17B
ASPHF [@Biotechnology] is valued at $3.44B. NURPF’s [@Biotechnology] market capitalization is $1.17B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASPHF’s FA Score shows that 0 FA rating(s) are green whileNURPF’s FA Score has 0 green FA rating(s).

  • ASPHF’s FA Score: 0 green, 5 red.
  • NURPF’s FA Score: 0 green, 5 red.
According to our system of comparison, NURPF is a better buy in the long-term than ASPHF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NURPF’s TA Score shows that 2 TA indicator(s) are bullish.

  • NURPF’s TA Score: 2 bullish, 4 bearish.

Price Growth

ASPHF (@Biotechnology) experienced а 0.00% price change this week, while NURPF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASPHF($3.44B) has a higher market cap than NURPF($1.17B). ASPHF YTD gains are higher at: 116.543 vs. NURPF (16.380).
ASPHFNURPFASPHF / NURPF
Capitalization3.44B1.17B294%
EBITDAN/AN/A-
Gain YTD116.54316.380711%
P/E RatioN/A12.44-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
NURPF: Fundamental Ratings
NURPF
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
PROFIT vs RISK RATING
1..100
51
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
48
P/E GROWTH RATING
1..100
84
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ASPHFNURPF
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
63%
Stochastic
ODDS (%)
N/A
Bullish Trend 3 days ago
54%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
63%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
62%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
9%
Bullish Trend 3 days ago
59%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
7%
Bullish Trend 3 days ago
57%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
63%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
NURPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGRVX47.880.56
+1.18%
MFS International Growth R4
ERLGX19.200.09
+0.47%
Eaton Vance Atlanta Capital Fcs Gr R6
WWSCX16.170.02
+0.12%
Keeley Small Cap Fund C
SVUIX38.520.04
+0.10%
NAA SMid Cap Value Institutional
OGMNX34.17-1.32
-3.72%
Invesco Gold & Special Minerals R

ASPHF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASPHF has been loosely correlated with NERV. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ASPHF jumps, then NERV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASPHF
1D Price
Change %
ASPHF100%
N/A
NERV - ASPHF
44%
Loosely correlated
-2.22%
GPCR - ASPHF
31%
Poorly correlated
N/A
NURPF - ASPHF
30%
Poorly correlated
N/A
PYPD - ASPHF
24%
Poorly correlated
-0.28%
GOSS - ASPHF
24%
Poorly correlated
-3.85%
More

NURPF and

Correlation & Price change

A.I.dvisor tells us that NURPF and ASPHF have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NURPF and ASPHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NURPF
1D Price
Change %
NURPF100%
N/A
ASPHF - NURPF
30%
Poorly correlated
N/A
TCRT - NURPF
24%
Poorly correlated
+2.19%
IMAB - NURPF
23%
Poorly correlated
+27.23%
CLSD - NURPF
23%
Poorly correlated
-5.06%
SRZN - NURPF
22%
Poorly correlated
+8.02%
More